Compare TEVA & AVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TEVA | AVB |
|---|---|---|
| Founded | 1901 | 1978 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 30.2B | 25.1B |
| IPO Year | N/A | 1994 |
| Metric | TEVA | AVB |
|---|---|---|
| Price | $31.87 | $183.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 15 |
| Target Price | $32.11 | ★ $205.70 |
| AVG Volume (30 Days) | ★ 10.3M | 1.1M |
| Earning Date | 01-28-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.82% |
| EPS Growth | N/A | ★ 12.03 |
| EPS | 0.62 | ★ 8.20 |
| Revenue | ★ $16,776,000,000.00 | $3,065,608,000.00 |
| Revenue This Year | $4.62 | $3.39 |
| Revenue Next Year | $0.34 | $4.14 |
| P/E Ratio | $51.43 | ★ $22.32 |
| Revenue Growth | 0.02 | ★ 6.50 |
| 52 Week Low | $12.47 | $166.73 |
| 52 Week High | $31.99 | $230.21 |
| Indicator | TEVA | AVB |
|---|---|---|
| Relative Strength Index (RSI) | 85.04 | 58.69 |
| Support Level | $28.00 | $178.37 |
| Resistance Level | $31.99 | $183.15 |
| Average True Range (ATR) | 0.61 | 3.02 |
| MACD | 0.02 | 0.71 |
| Stochastic Oscillator | 95.37 | 93.70 |
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
AvalonBay Communities owns a portfolio of 295 apartment communities with almost 90,000 units and is developing 20 additional properties with approximately 7,300 units. The company focuses on owning large, high-quality properties in major metropolitan areas of New England, New York/New Jersey, Washington, D.C., California, and the Pacific Northwest.